Hydroxyzine and Deferasirox drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hydroxyzine (hydroxyzine hydrochloride) and Deferasirox (deferasirox). Common drug interactions include febrile neutropenia among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Hydroxyzine and Deferasirox. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Hydroxyzine?

Hydroxyzine has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 54,069 Hydroxyzine users. Check the latest studies of Hydroxyzine.

What is Deferasirox?

Deferasirox has active ingredients of deferasirox. eHealthMe is studying from 2,641 Deferasirox users. Check the latest studies of Deferasirox.



On Jul, 19, 2026

11 people who take Hydroxyzine and Deferasirox together, and have interactions are studied.

Hydroxyzine and Deferasirox drug interactions.

What are the common drug interactions of Hydroxyzine and Deferasirox, by gender? *:

female:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
  3. Gastritis (inflammation of stomach)
  4. Hypertension (high blood pressure)
  5. Rhinitis allergic (inflammation of the nasal airways due to allergy)
  6. Death
  7. Abdominal distension
  8. Acute leukaemia (blood cancer)
  9. Adenovirus infection
  10. Anal haemorrhage

male:

  1. Pyrexia (fever)
  2. Decreased appetite
  3. Pain in extremity
  4. Platelet count decreased
  5. Pleural effusion (water on the lungs)
  6. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  7. Weight increased
  8. Arthralgia (joint pain)
  9. C-reactive protein increased
  10. Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Hydroxyzine and Deferasirox, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Pyrexia (fever)
  2. Decreased appetite
  3. Diarrhoea
  4. Eosinophil count increased
  5. Nausea (feeling of having an urge to vomit)
  6. Abdominal pain
  7. Anaemia (lack of blood)
  8. Back pain
  9. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
  10. Oxygen saturation decreased

10-19:

  1. Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
  2. Febrile neutropenia (fever with reduced white blood cells)
  3. Gastritis (inflammation of stomach)
  4. Hypertension (high blood pressure)
  5. Rhinitis allergic (inflammation of the nasal airways due to allergy)

20-29:

  1. Adenovirus infection

30-39:

n/a

40-49:

  1. Abdominal distension
  2. Anal haemorrhage
  3. Asthenia (weakness)
  4. Decreased appetite
  5. Febrile neutropenia (fever with reduced white blood cells)
  6. Gingival bleeding (bleeding gums)
  7. Gingival swelling (gums swelling)
  8. Hypokalaemia (low potassium)
  9. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  10. Petechiae (a small red or purple spot caused by bleeding into the skin)

50-59:

n/a

60+:

  1. Red blood cell count decreased
  2. Anaemia (lack of blood)
  3. Back pain
  4. Basophil count increased
  5. Blast cell count increased
  6. Blood albumin decreased
  7. Blood alkaline phosphatase increased
  8. Blood bilirubin increased
  9. Blood calcium decreased
  10. Diarrhoea

What are the existing conditions these people have? *

  1. Iron Overload: 6 people, 54.55%
  2. Bone Marrow Conditioning Regimen: 3 people, 27.27%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 27.27%
  4. Weight Increased: 2 people, 18.18%
  5. Gastritis (inflammation of stomach): 2 people, 18.18%
  6. Aplastic Anemia: 2 people, 18.18%
  7. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 18.18%
  8. Back Pain: 2 people, 18.18%
  9. Oedema (fluid collection in tissue): 2 people, 18.18%
  10. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Hydroxyzine and Deferasirox?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Hydroxyzine and Deferasirox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Hydroxyzine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Deferasirox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydroxyzine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Deferasirox and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride and deferasirox (the active ingredients of Hydroxyzine and Deferasirox, respectively), and Hydroxyzine and Deferasirox (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: